Apollo Hospitals

AHold / Watchlist

APOLLOHOSP · NSE · Large Cap · Pharmacy Retail

Pharmacy Retail

Fetching live…

₹6,900

1D 0.5%1M 3.0%1Y 18%

Fundamental (RQ-100)

Technical (TQ-100)

Valuation

Market cap

₹1.00L Cr

Live decision ratingB+Hold

Fundamental score breakdown

70/100

Growth Quality

14.4 / 20

Rev 1Y 16.0%, 3Y CAGR 18.0%, 5Y CAGR 14.0%

Margin & Profitability

8.3 / 15

EBITDA 14.0%, PAT 6.0%

Return on Capital

14.0 / 20

ROCE 18.0%, ROE 14.0%

Cash Flow Quality

10.0 / 15

OCF/EBITDA 0.75

Leverage

6.0 / 10

ND/EBITDA 1.80

Reinvestment

8.0 / 8

Capex/Sales 8.0%

Accounting

5.0 / 7

Governance

4.0 / 5

Technical score breakdown

49/100

Trend Structure

8.0 / 20

↓ 200 · ↓ 50 · ↓ 20

Momentum

8.0 / 15

1Y 18.0%, 1M 3.0%

Volume Dynamics

8.0 / 15

Vol30 —%

Relative Strength

10.0 / 15

1Y 18.0%

MA Cluster

5.0 / 10

Extension

5.0 / 10

—% from 50DMA

Volatility

4.0 / 8

Price Action

1.0 / 7

-100.0% from 52W H

Business

What this company actually does

Hospitals + Apollo Pharmacy + Apollo 24/7. Pharmacy via Apollo Healthco.

Stores

—

Dark stores

—

Cities

—

Listed status

Listed

Format exposure

How direct is this play?

Primary formatPharmacy Retail

Exposure typeAncillary

Revenue visibilityHigh

Operating leverage stageScaling

Policy beneficiaryNone

Data confidenceMedium

Financial snapshot

Live · green dot = live, falls back to curated

Revenue

₹22.0K Cr

Rev 1Y growth

16%

Rev 3Y CAGR

18%

EBITDA margin

14.0%

PAT margin

6.0%

ROE

14%

ROCE

18%

OCF/EBITDA

0.75

Net Debt/EBITDA

1.8

Financial statements

Multi-year P&L, balance sheet, cash flow — scraped live from Screener.in

Fetching from Screener.in…

Loading…

Valuation

Live multiples + retail-specific (curated)

P/E

Forward P/E

EV/EBITDA

EV/Sales

4.5

P/B

12.0

FCF Yield

1.3%

Mid-range valuation. Watch incremental ROCE.

Investment thesis

AI-generated · always cite sources before acting

Bull

Best-in-class 18% ROCE with 0.75 OCF conversion. Technical setup constructive — stock above key moving averages.

Base

Earnings growth of ~20% over the next 3 years assuming margins hold. Multiple compression risk if growth slows; multiple expansion possible if Pharmacy Retail GMV outperforms.

Bear

Format-level risk: regulation, gig-cess, or competitive pressure compress contribution margin.

Variant perception

Consensus views Apollo Hospitals as a quality compounder. Our differentiated take: the cyclical pessimism in Pharmacy Retail has overshot the long-term cash-flow potential.

Key monitorables

Quarterly EBITDA margin trajectory
Revenue growth vs management guidance
Capex discipline (currently elevated)
Promoter holding and ESOP dilution

Peers

Same primary format · sorted by market cap